← Back to patent-cliff list
Carbetocin intranasal (Ferring Pharmaceuticals)
Tier C — Watch / tradeCarbetocin intranasal (Ferring Pharmaceuticals)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：OT-R
Indications (approved)：Prader-Willi综合征, 摄食过度
Regional status
US
Phase III
2018-11-20
EU
Phase III
2023-11-27
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Carbetocin intranasal (Ferring Pharmaceuticals)?
Approved indications include: Prader-Willi综合征, 摄食过度.
When does the Carbetocin intranasal (Ferring Pharmaceuticals) patent expire?
No public expiry year is available for Carbetocin intranasal (Ferring Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Carbetocin intranasal (Ferring Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08